Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pegylated interferons.

D E Baker1

  • 1Washington State University, Spokane, WA, USA.

Reviews in Gastroenterological Disorders
|July 18, 2002
PubMed
Summary
This summary is machine-generated.

Pegylated interferon therapy for chronic hepatitis C reduces viral load and complications. Pegylation enhances drug activity and allows less frequent dosing compared to nonpegylated interferon.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monitoring and assessment of soil and forage molybdenum near an atmospheric source.

Environmental monitoring and assessment·2013
Same author

Force spectroscopy of hepatocytic extracellular matrix components.

Ultramicroscopy·2009
Same author

Esomeprazole magnesium (Nexium).

Reviews in gastroenterological disorders·2002
Same author

Budesonide modified-release capsules.

Reviews in gastroenterological disorders·2002
Same author

Tegaserod for the treatment of constipation-predominant irritable bowel syndrome.

Reviews in gastroenterological disorders·2002
Same author

Nateglinide therapy for type 2 diabetes mellitus.

The Annals of pharmacotherapy·2001
Same journal

Prevalence and risk factors of fecal incontinence in community-dwelling men.

Reviews in gastroenterological disorders·2010
Same journal

Diarrhea - novel transdermal patch vaccine to prevent travelers' diarrhea.

Reviews in gastroenterological disorders·2010
Same journal

Peptic ulcer bleeding following therapeutic endoscopy: a new indication for intravenous esomeprazole.

Reviews in gastroenterological disorders·2010
Same journal

Diarrhea--cryptosporidial diarrhea in patients with AIDS: impressive results with Rifaximin.

Reviews in gastroenterological disorders·2009
Same journal

Methylnaltrexone bromide: new drug for the treatment of opioid-induced bowel dysfunction.

Reviews in gastroenterological disorders·2009
Same journal

Antimicrobial resistance and eradication strategies for Helicobacter pylori.

Reviews in gastroenterological disorders·2009
See all related articles

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis C infection poses risks of cirrhosis, liver failure, and cancer.
  • Interferon therapy can decrease viral load but is not a cure.
  • Pegylation modifies interferon to improve its pharmacokinetic profile.

Purpose of the Study:

  • To review the characteristics and efficacy of pegylated interferon alfa in treating chronic hepatitis C.
  • To compare pegylated interferon alfa with nonpegylated formulations.

Main Methods:

  • Review of pharmacokinetic principles of pegylation.
  • Analysis of clinical response data for interferon-based therapies.
  • Comparison of monotherapy versus combination therapy.

Related Experiment Videos

Main Results:

  • Pegylation increases interferon's half-life and duration of action.
  • Pegylated interferons allow for less frequent administration than nonpegylated forms.
  • Both formulations show comparable tolerability, with some patients responding better to pegylated versions.

Conclusions:

  • Pegylated interferon alfa offers improved dosing convenience and comparable tolerability to nonpegylated interferon.
  • Combination therapy with ribavirin is more effective than monotherapy for chronic hepatitis C.
  • Direct comparative studies between peginterferon alfa-2b and peginterferon alfa-2a are lacking.